Table 1.
Clinical characteristics of the study population in the mid-trimester cohort.
| Controls (did not develop preeclampsia) (n = 66) | Cases (developed preeclampsia) (n = 33) | p Value | |
|---|---|---|---|
| Maternal age (years) | 36 (27–43) | 35 (26–44) | NS |
| Nulliparity | 39 (59%) | 20 (61%) | NS |
| BMI before pregnancy | 20.7 (16.4–32.8) (n = 51) | 22.4 (17.6–40.2) (n = 31) | < 0.01 |
| BMI at blood sampling | 22.4 (16.7–36.5) | 23.8 (18.2–38.1) | NS |
| Gestational age at blood sampling (weeks) | 17.4 (16.0–23.4) | 17.6 (16.0–22.6) | NS |
| Gestational age at delivery (weeks) | 39.3 (25.6–42.3) | 37.4 (25.3–41.3) | < 0.001 |
| Birth weight (g) | 3275 (760–4260) | 2670 (450–4700) | < 0.001 |
| Small for gestational age | 4 (6%) | 6 (19%) | NS |
| Sex (male) | 34 (53%) | 16 (49%) | NS |
| Cesarean delivery | 26 (41%) | 16 (49%) | NS |
| Diabetes during pregnancy | 1 (2%) | 0 (0%) | NS |
| Pro- and anti-angiogenic factors | |||
| sFlt-1 (pg/mL) | 887.4 (177.3–3446.2) | 952.2 (273.7–1957.1) | NS |
| PlGF (pg/mL) | 60.3 (11.3–654.4) | 43.1 (3.2–387.8) | < 0.05 |
| sFlt-1/PlGF | 15.1 (0.8–239.2) | 18.0 (1.5–577.8) | NS |
All values are given as median (range) or number (%).
NS, not significant; BMI, body mass index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1.